Details der Publikation - Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation

Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation

Medienart:	E-Artikel

Erscheinungsjahr:	2020
Erschienen:	2020

Enthalten in:	Zur Gesamtaufnahme - volume:76
Enthalten in:	European journal of clinical pharmacology - 76(2020), 5 vom: 25. Jan., Seite 735-737

Sprache:	Englisch

Beteiligte Personen:	Vieira, Carolina Pinto [VerfasserIn] Neves, Daniel Valente [VerfasserIn] Nardotto, Glauco Henrique Balthazar [VerfasserIn] Cesarino, Evandro José [VerfasserIn] Rocha, Adriana [VerfasserIn] Zanardi, Ailton Marcelo Castilho Teno [VerfasserIn] Lanchote, Vera Lucia [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Themen:	Chagas disease Elderly patients Metabolism Nebivolol Pharmacokinetics

RVK:	RVK Klassifikation ELIB24

Anmerkungen:	© Springer-Verlag GmbH Germany, part of Springer Nature 2020

doi:	10.1007/s00228-020-02837-9

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC211732780X

Internformat


LEADER	01000naa a22002652 4500
001	OLC211732780X
003	DE-627
005	20230504132523.0
007	cr uuu---uuuuu
008	230504s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s00228-020-02837-9 \|2 doi
035			\|a (DE-627)OLC211732780X
035			\|a (DE-He213)s00228-020-02837-9-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a PHARM \|q DE-84 \|2 fid
084			\|a ELIB24 \|q VZ \|2 rvk
100	1		\|a Vieira, Carolina Pinto \|e verfasserin \|4 aut
245	1	0	\|a Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Springer-Verlag GmbH Germany, part of Springer Nature 2020
650		4	\|a Nebivolol
650		4	\|a Metabolism
650		4	\|a Elderly patients
650		4	\|a Pharmacokinetics
650		4	\|a Chagas disease
700	1		\|a Neves, Daniel Valente \|4 aut
700	1		\|a Nardotto, Glauco Henrique Balthazar \|0 (orcid)0000-0001-7024-4252 \|4 aut
700	1		\|a Cesarino, Evandro José \|4 aut
700	1		\|a Rocha, Adriana \|4 aut
700	1		\|a Zanardi, Ailton Marcelo Castilho Teno \|4 aut
700	1		\|a Lanchote, Vera Lucia \|0 (orcid)0000-0002-0074-4953 \|4 aut
773	0	8	\|i Enthalten in \|t European journal of clinical pharmacology \|d Springer Berlin Heidelberg, 1968 \|g 76(2020), 5 vom: 25. Jan., Seite 735-737 \|h Online-Ressource \|w (DE-627)253722829 \|w (DE-600)1459058-X \|w (DE-576)072372613 \|x 1432-1041 \|7 nnns
773	1	8	\|g volume:76 \|g year:2020 \|g number:5 \|g day:25 \|g month:01 \|g pages:735-737
856	4	0	\|u https://dx.doi.org/10.1007/s00228-020-02837-9 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a FID-PHARM
912			\|a SSG-OPC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_267
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2134
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2433
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	r	v	\|a ELIB24
951			\|a AR
952			\|d 76 \|j 2020 \|e 5 \|b 25 \|c 01 \|h 735-737

Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände